CA1043208A - Dispensing lung contacting powdered medicaments - Google Patents
Dispensing lung contacting powdered medicamentsInfo
- Publication number
- CA1043208A CA1043208A CA194,459A CA194459A CA1043208A CA 1043208 A CA1043208 A CA 1043208A CA 194459 A CA194459 A CA 194459A CA 1043208 A CA1043208 A CA 1043208A
- Authority
- CA
- Canada
- Prior art keywords
- container
- aerosol
- button
- chamber
- mouthpiece
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 210000004072 lung Anatomy 0.000 title abstract description 20
- 239000000443 aerosol Substances 0.000 claims abstract description 54
- 239000002245 particle Substances 0.000 claims abstract description 23
- 239000003380 propellant Substances 0.000 claims description 27
- BDLFTHFBZRBSSL-UHFFFAOYSA-N 4-[(3-carboxy-2-hydroxynaphthalen-1-yl)methyl]-3-hydroxynaphthalene-2-carboxylic acid;n,n-diethyl-4-methylpiperazine-1-carboxamide Chemical compound CCN(CC)C(=O)N1CCN(C)CC1.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 BDLFTHFBZRBSSL-UHFFFAOYSA-N 0.000 claims description 9
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 claims description 8
- 229960002117 triamcinolone acetonide Drugs 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 7
- 239000004479 aerosol dispenser Substances 0.000 claims description 6
- 239000000428 dust Substances 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 5
- 238000007789 sealing Methods 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims 2
- 239000000843 powder Substances 0.000 abstract description 12
- 230000009885 systemic effect Effects 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 5
- 230000000699 topical effect Effects 0.000 abstract 1
- 239000007921 spray Substances 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 238000007600 charging Methods 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000007787 solid Substances 0.000 description 11
- RCKMWOKWVGPNJF-UHFFFAOYSA-N diethylcarbamazine Chemical compound CCN(CC)C(=O)N1CCN(C)CC1 RCKMWOKWVGPNJF-UHFFFAOYSA-N 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000004033 plastic Substances 0.000 description 9
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 8
- 229920003023 plastic Polymers 0.000 description 8
- 229910001220 stainless steel Inorganic materials 0.000 description 8
- 239000010935 stainless steel Substances 0.000 description 8
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 239000005909 Kieselgur Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 230000000994 depressogenic effect Effects 0.000 description 5
- 229960003974 diethylcarbamazine Drugs 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- PGNKBEARDDELNB-UHFFFAOYSA-N Diethylcarbamazine citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCN(CC)C(=O)N1CCN(C)CC1 PGNKBEARDDELNB-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 230000000712 assembly Effects 0.000 description 3
- 238000000429 assembly Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 2
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 2
- UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- YSVZGWAJIHWNQK-UHFFFAOYSA-N [3-(hydroxymethyl)-2-bicyclo[2.2.1]heptanyl]methanol Chemical compound C1CC2C(CO)C(CO)C1C2 YSVZGWAJIHWNQK-UHFFFAOYSA-N 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229910052729 chemical element Inorganic materials 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229940099364 dichlorofluoromethane Drugs 0.000 description 1
- 229960004837 diethylcarbamazine citrate Drugs 0.000 description 1
- YGLLICRFEVEWOZ-UHFFFAOYSA-L disodium;3-carboxy-1-[(3-carboxy-2-oxidonaphthalen-1-yl)methyl]naphthalen-2-olate Chemical compound [Na+].[Na+].C1=CC=C2C(CC3=C4C=CC=CC4=CC(=C3O)C([O-])=O)=C(O)C(C([O-])=O)=CC2=C1 YGLLICRFEVEWOZ-UHFFFAOYSA-L 0.000 description 1
- DNQSGXVJKQBSMT-UHFFFAOYSA-L disodium;3-carboxy-1-[(3-carboxy-2-oxidonaphthalen-1-yl)methyl]naphthalen-2-olate;hydrate Chemical compound O.[Na+].[Na+].C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3[O-])C(=O)O)=C([O-])C(C(O)=O)=CC2=C1 DNQSGXVJKQBSMT-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US00374176A US3809294A (en) | 1973-06-27 | 1973-06-27 | Dispensing lung contacting powdered medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1043208A true CA1043208A (en) | 1978-11-28 |
Family
ID=23475640
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA194,459A Expired CA1043208A (en) | 1973-06-27 | 1974-03-08 | Dispensing lung contacting powdered medicaments |
Country Status (24)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3998226A (en) * | 1975-09-22 | 1976-12-21 | Edward G. Gomez | Inhalation device for encapsulated concentrates |
| US3994421A (en) * | 1975-09-29 | 1976-11-30 | American Cyanamid Company | Unitary therapeutic aerosol dispenser |
| SE408265B (sv) * | 1975-12-12 | 1979-06-05 | Draco Ab | Anordning for koldioxiddriven endosaerosol, avsedd for inhalering |
| GR69682B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1978-09-11 | 1982-07-08 | Newhouse Michael T | |
| DE3348370C2 (de) * | 1982-10-08 | 2001-10-11 | Glaxo Group Ltd | Medikamenten-Packung und Verfahren zur Erzeugung eines zur Inhalation bestimmten Medikamenten-Pulver-Luftstroms |
| IT1217890B (it) * | 1988-06-22 | 1990-03-30 | Chiesi Farma Spa | Dispositivo per l'inalazione di aerosol dosati |
| US5169639A (en) * | 1988-09-19 | 1992-12-08 | Edward Mendell Co., Inc. | Controlled release verapamil tablets |
| US5040527A (en) * | 1990-12-18 | 1991-08-20 | Healthscan Products Inc. | Metered dose inhalation unit with slide means |
| US5186164A (en) * | 1991-03-15 | 1993-02-16 | Puthalath Raghuprasad | Mist inhaler |
| US5993805A (en) * | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
| US5744123A (en) * | 1991-12-12 | 1998-04-28 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicaments |
| IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
| US5658549A (en) * | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
| US5653962A (en) * | 1991-12-12 | 1997-08-05 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicaments |
| US5916540A (en) * | 1994-10-24 | 1999-06-29 | Glaxo Group Limited | Aerosol formulations containing P134A and/or P227 and particulate medicament |
| US5736124A (en) * | 1991-12-12 | 1998-04-07 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicament |
| US5674471A (en) * | 1991-12-12 | 1997-10-07 | Glaxo Group Limited | Aerosol formulations containing P134a and salbutamol |
| WO1993011744A1 (en) * | 1991-12-12 | 1993-06-24 | Glaxo Group Limited | Medicaments |
| AU663906B2 (en) * | 1991-12-12 | 1995-10-26 | Glaxo Group Limited | Medicaments |
| US7101534B1 (en) | 1991-12-18 | 2006-09-05 | 3M Innovative Properties Company | Suspension aerosol formulations |
| ES2159678T3 (es) | 1991-12-18 | 2001-10-16 | Minnesota Mining & Mfg | Formulaciones de aerosol en suspension. |
| US7105152B1 (en) | 1991-12-18 | 2006-09-12 | 3M Innovative Properties Company | Suspension aerosol formulations |
| GB9322014D0 (en) * | 1993-10-26 | 1993-12-15 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
| US5839429A (en) * | 1994-03-25 | 1998-11-24 | Astra Aktiebolag | Method and apparatus in connection with an inhaler |
| US5598836A (en) * | 1995-05-26 | 1997-02-04 | Healthscan Products, Inc. | Metered dose inhalation unit with slide means |
| US5976573A (en) * | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
| DE19740617A1 (de) * | 1997-09-16 | 1999-03-18 | Palas Gmbh | Verfahren und Vorrichtung zum Erzeugen eines Feststoff-Aerosols |
| US6345617B1 (en) | 1997-09-26 | 2002-02-12 | 1263152 Ontario Inc. | Aerosol medication delivery apparatus and system |
| US6293279B1 (en) | 1997-09-26 | 2001-09-25 | Trudell Medical International | Aerosol medication delivery apparatus and system |
| CA2733850C (en) | 2000-04-11 | 2013-10-22 | Trudell Medical International | Aerosol delivery apparatus with positive expiratory pressure capacity |
| CA2445516C (en) * | 2001-04-26 | 2007-11-20 | New England Pharmaceuticals, Inc. | Metered dose delivery device for liquid and powder agents |
| GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
| US7582284B2 (en) * | 2002-04-17 | 2009-09-01 | Nektar Therapeutics | Particulate materials |
| US20030205226A1 (en) * | 2002-05-02 | 2003-11-06 | Pre Holding, Inc. | Aerosol medication inhalation system |
| US6904908B2 (en) | 2002-05-21 | 2005-06-14 | Trudell Medical International | Visual indicator for an aerosol medication delivery apparatus and system |
| WO2005025506A2 (en) * | 2003-09-10 | 2005-03-24 | Map Pharmaceuticals, Inc. | Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation |
| US8365725B2 (en) * | 2004-09-13 | 2013-02-05 | Oriel Therapeutics, Inc. | Dry powder inhalers that inhibit agglomeration, related devices and methods |
| NL1027255C2 (nl) * | 2004-10-15 | 2006-04-19 | Lab Tickner Ag | Inrichting voor het verwijderen van een teek. |
| ES2691033T3 (es) * | 2007-02-11 | 2018-11-23 | Map Pharmaceuticals Inc. | Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios |
| WO2010151804A1 (en) * | 2009-06-26 | 2010-12-29 | Map Pharmaceuticals, Inc. | Administration of dihydroergotamine mesylate particles using a metered dose inhaler |
| CA156938S (en) | 2013-02-14 | 2014-07-08 | Clement Clarke Int Ltd | Spacer for an asthma inhaler |
| US10207065B2 (en) | 2013-07-12 | 2019-02-19 | John H. Silva | Mouthpiece for inhalers |
| USD748242S1 (en) * | 2014-07-11 | 2016-01-26 | H. Stuart Campbell | Inhaler mouthpiece |
| EP4255418A4 (en) * | 2020-12-01 | 2025-04-23 | Reverspah LLC | METHODS AND COMPOSITIONS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE, ASTHMA, CHRONIC BRONCHITIS, CYSTIC FIBROSIS, PULMONARY EDEMA, INTERSTITIAL LUNG DISEASE, SARCOIDOSIS, IDIOPATHIC PULMONARY FIBROSIS, ACUTE RESPIRATORY DISTRESS SYNDROME, AND PULMONARY ARTERIAL HYPERTENSION |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE555972A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1956-03-21 | |||
| US2890697A (en) * | 1957-03-15 | 1959-06-16 | Wilton E Van Sickle | Enclosed medicament container and atomizer |
| US3012555A (en) * | 1959-05-18 | 1961-12-12 | Meshberg Philip | Dispensing package for material under pressure |
| US3183907A (en) * | 1962-06-25 | 1965-05-18 | Merck & Co Inc | Device for inhalation aerosol |
| JPS4214552Y1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1964-12-30 | 1967-08-18 | ||
| JPS4514212Y1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1966-11-02 | 1970-06-16 | ||
| US3559851A (en) * | 1969-05-27 | 1971-02-02 | Valve Corp Of America | Fully-emptying valve assemblage |
| JPS566680Y2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * | 1972-04-19 | 1981-02-13 |
-
1973
- 1973-06-27 US US00374176A patent/US3809294A/en not_active Expired - Lifetime
-
1974
- 1974-03-08 CA CA194,459A patent/CA1043208A/en not_active Expired
- 1974-03-12 IL IL44401A patent/IL44401A/en unknown
- 1974-03-12 ZA ZA00741633A patent/ZA741633B/xx unknown
- 1974-03-19 IE IE574/74A patent/IE40616B1/xx unknown
- 1974-03-21 PH PH15648A patent/PH11643A/en unknown
- 1974-03-21 GB GB1270674A patent/GB1471917A/en not_active Expired
- 1974-03-28 AR AR253017A patent/AR198562A1/es active
- 1974-03-29 DE DE2415360A patent/DE2415360C2/de not_active Expired
- 1974-04-02 IT IT49957/74A patent/IT1003994B/it active
- 1974-04-04 NL NLAANVRAGE7404626,A patent/NL178655C/xx not_active IP Right Cessation
- 1974-04-08 DD DD177768A patent/DD125188A5/xx unknown
- 1974-04-09 SU SU2017264A patent/SU537614A3/ru active
- 1974-04-09 BE BE143026A patent/BE813512A/xx not_active IP Right Cessation
- 1974-04-09 YU YU00989/74A patent/YU36435B/xx unknown
- 1974-04-10 AT AT299974A patent/AT342211B/de not_active IP Right Cessation
- 1974-04-10 FR FR7412670A patent/FR2234905B1/fr not_active Expired
- 1974-04-10 JP JP49041581A patent/JPS6010737B2/ja not_active Expired
- 1974-04-11 SE SE7405022A patent/SE405448B/xx unknown
- 1974-04-23 CH CH555174A patent/CH577832A5/xx not_active IP Right Cessation
- 1974-06-25 PL PL1974172163A patent/PL89980B1/pl unknown
- 1974-06-26 DK DK343874A patent/DK152967C/da not_active IP Right Cessation
- 1974-06-27 CS CS7400004539A patent/CS182257B2/cs unknown
- 1974-06-27 ES ES427755A patent/ES427755A1/es not_active Expired
-
1975
- 1975-10-13 CH CH1325075A patent/CH620207A5/de not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1043208A (en) | Dispensing lung contacting powdered medicaments | |
| US3895111A (en) | Asthma treatment by inhalation of micronized N,N-diethyl-4-methyl-1-piperazinecarboxamide pamoate | |
| AU666979B2 (en) | Powder inhaler | |
| US5239993A (en) | Dosage inhalator providing optimized compound inhalation trajectory | |
| EP1019127B1 (en) | Aerosol medication delivery apparatus | |
| EP0015247B1 (en) | An aerosol inhalation device | |
| CA1038346A (en) | Unitary therapeutic aerosol dispenser | |
| US4570630A (en) | Medicament inhalation device | |
| EP0773807B1 (en) | Inhalation device | |
| US20080190424A1 (en) | Unit dose dry powder inhaler | |
| EP0079478A1 (en) | Medicament inhalation device | |
| JPS61500831A (ja) | 吸入装置 | |
| AU2018204860B2 (en) | Inhalable medicaments | |
| IE45837B1 (en) | Device for use with pressurised aerosol type medicinal inhalation devices | |
| CA2396273C (en) | Aerosol inhaler | |
| EP0774986B1 (en) | Inhaler apparatus with optimisation chamber | |
| JP2004503492A (ja) | アルファ４−インテグリンアンタゴニスト含有の吸入用乾燥粉末状医薬製剤 | |
| HK40017650A (en) | Inhalable medicaments | |
| MXPA06006284A (en) | Portable gas operating inhaler |